Search
Genmab A/S
GMABAdd to Watchlist
26.020USD
-0.100-0.38%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
16.38BMarket Cap
19.60P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.38%
5 Days
+1.60%
1 Month
-1.18%
6 Months
-19.99%
Year to Date
-15.52%
1 Year
+26.93%
Key Figures
26.230Open
26.420High
2.03MVolume
19.60P/E TTM
13.59P/E Dynamic
--Dividend TTM
0.33%Turnover Ratio
26.120Prev. Close
25.970Low
39.08MTurnover
14.09P/E Static
2.74P/B
0.00%Div Yield TTM
8.66%ROA
35.43052wk High
1.39Volume Ratio
1.14BNet Profit
616.19MShares
1.3275EPS TTM
0.87Beta
14.96%ROE
20.22552wk Low
1.72%Amplitude
92.75%Gross Margin
16.38BMarket Cap
-0.54Reward/Risk
1.47%Risk Rate
TradingKey Stock Score of Genmab A/S
Currency: USD Updated: 2026-06-29Key Insights
Genmab A/S's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.31.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Genmab A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Genmab A/S Highlights
StrengthsRisks
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.58% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.72B.
Overvalued
The company’s latest PE is 19.60, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.31M shares, decreasing 3.87% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 212.65K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
38.308
Target Price
+46.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Genmab A/S News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Genmab A/S Info
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Ticker SymbolGMAB
CompanyGenmab A/S
CEOVan De Winkel (Jan G.J)
Websitehttps://www.genmab.com/
Related Instruments
+1.74%
+1.48%
+0.30%
+0.56%
+1.38%
+1.38%
+0.62%
+0.56%
-1.21%
+0.39%
+1.69%
+1.79%
+0.59%
+1.12%
-2.09%
0.00%
-0.17%
+2.85%
-0.74%
+0.47%Popular Instruments
FAQs
What is the current price of Genmab A/S (GMAB)?
The current price of Genmab A/S (GMAB) is 26.02.
What is the symbol of Genmab A/S?
The ticker symbol of Genmab A/S is GMAB.
What is the 52-week high of Genmab A/S?
The 52-week high of Genmab A/S is 35.43.
What is the 52-week low of Genmab A/S?
The 52-week low of Genmab A/S is 20.23.
What is the market capitalization of Genmab A/S?
The market capitalization of Genmab A/S is 16.03B.
Is Genmab A/S (GMAB) currently rated as Buy, Hold, or Sell?
According to analysts, Genmab A/S (GMAB) has an overall rating of Buy, with a price target of 38.31.
What is the Earnings Per Share (EPS TTM) of Genmab A/S (GMAB)?
The Earnings Per Share (EPS TTM) of Genmab A/S (GMAB) is 1.55.
